Free Trial
LON:DXRX

Diaceutics Interim Earnings Report

Diaceutics logo
GBX 145 -8.00 (-5.23%)
As of 11:45 AM Eastern

Diaceutics EPS Results

Actual EPS
-GBX 2.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Diaceutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Diaceutics Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Diaceutics Earnings Headlines

Diaceutics (LON:DXRX) Stock Price Down 7.1% - Here's Why
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.tc pixel
Diaceutics PLC Expands Employee Share Incentive Plan
See More Diaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email.

About Diaceutics

At Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

View Diaceutics Profile